ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
MWN-AI** Summary
ADMA Biologics, Inc. (Nasdaq: ADMA), a specialized biopharmaceutical company based in the U.S., has announced it will report its fourth quarter and full year financial results for 2025 on February 25, 2026, after the close of U.S. financial markets. The company’s management will host a live conference call and audio webcast at 4:30 p.m. ET the same day to reveal the financial results and provide updates on company developments. Participants wishing to join the call must register in advance for dial-in information, while those opting not to ask questions may listen through the live webcast.
ADMA is committed to the development, marketing, and manufacture of specialty biologics aimed at treating immunodeficient patients and addressing specific infectious diseases. Currently, the company markets three FDA-approved plasma-derived biologics: ASCENIV™ for primary humoral immunodeficiency (PI), BIVIGAM® for PI treatment, and NABI-HB® to enhance immunity against hepatitis B virus. The company also has a pre-clinical candidate, SG-001, which targets S. pneumonia.
Manufacturing takes place at ADMA's FDA-licensed facility in Boca Raton, Florida, while its ADMA BioCenters subsidiary serves as an FDA-approved source plasma collector in the U.S., supplying the essential blood plasma for its products. With multiple U.S. and foreign patents, ADMA's focus remains on producing human immune globulins for niche patient populations, particularly managing immune deficiencies and preventing infectious diseases. For further details, stakeholders are encouraged to visit the company’s website.
MWN-AI** Analysis
As ADMA Biologics prepares to report its fourth quarter and full year 2025 financial results on February 25, 2026, investors should closely monitor several key indicators that will shape the company’s stock performance moving forward. The live conference call following the earnings report will provide critical insights into ADMA's financial health, operational performance, and strategic direction.
ADMA Biologics operates in a niche market focused on specialty biologics for immunodeficient patients, a sector that is seeing increasing demand due to an aging population and rising incidence of autoimmune disorders. The company’s existing portfolio, which includes FDA-approved products like ASCENIV™, BIVIGAM®, and NABI-HB®, positions it favorably in the treatment of immune deficiencies. Investors should pay attention to any updates regarding the sales growth of these products during the reported quarter, as this will offer a glimpse into the company’s market traction.
Additionally, the developments surrounding ADMA's investigational product SG-001, which targets S. pneumonia, are of paramount importance. Investors should look for updates on the product development timeline and any potential results from pre-clinical studies, as successful progression could significantly impact the company's growth trajectory.
Another aspect to consider is ADMA's operational efficiency and cost management practices. With the rising costs of biopharmaceutical manufacturing, any commentary related to production capabilities, cost containment measures, and supply chain management will be vital for assessing the company's profitability outlook.
In summary, investors should approach ADMA Biologics with an eye on the earnings call for updates on sales performance, product development, and operational efficiency. Positive developments in these areas could enhance investor confidence and support stock performance in the coming months.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report fourth quarter and full year 2025 financial results on February 25, 2026, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.
To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts.
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Additionally, ADMA is developing SG-001, a pre-clinical, investigative hyperimmune globulin targeting S. pneumonia. ADMA manufactures its immune globulin products and product candidates at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com.
INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | ADMA@argotpartners.com
FAQ**
How does the geographical presence of ADMA Biologics Inc (ADMA) in Ramsey, NJ, and Boca Raton, FL, influence its operational efficiency and supply chain logistics?
What role does ADMA Biologics Inc (ADMA) play in the local economies of Ramsey, NJ, and Boca Raton, FL, particularly in terms of employment and community investment?
How do the regulatory environments in Ramsey, NJ, and Boca Raton, FL, affect the research and development capabilities of ADMA Biologics Inc (ADMA)?
What advantages does ADMA Biologics Inc (ADMA) gain from its FDA-licensed manufacturing facility located in Boca Raton, FL, in comparison to its operations in Ramsey, NJ?
**MWN-AI FAQ is based on asking OpenAI questions about ADMA Biologics Inc (NASDAQ: ADMA).
NASDAQ: ADMA
ADMA Trading
2.36% G/L:
$16.025 Last:
547,760 Volume:
$15.69 Open:
